We serve Chemical Name:U0126 CAS:109511-58-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:U0126
CAS.NO:109511-58-2
Synonyms:(2Z,3Z)-2,3-bis[amino-(2-aminophenyl)sulfanylmethylidene]butanedinitrile;Butanedinitrile, 2,3-bis[amino[(2-aminophenyl)thio]methylene]-, (2Z,3Z)-;U 0126;(2Z,3Z)-Bis{amino[(2-aminophenyl)sulfanyl]methylene}succinonitrile;(2Z,3Z)-bis{amino[(2-aminophenyl)sulfanyl]methylidene}butanedinitrile;U0126;U-0126
Molecular Formula:C18H16N6S2
Molecular Weight:380.490
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:565.1±50.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.762
PSA:202.26000
Exact Mass:380.087799
LogP:-1.07
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (2Z,3Z)-2,3-bis[amino-(2-aminophenyl)sulfanylmethylidene]butanedinitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,U-0126 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2Z,3Z)-Bis{amino[(2-aminophenyl)sulfanyl]methylene}succinonitrile Use and application,U0126 technical grade,usp/ep/jp grade.
Related News: Our pharma and biotech offering includes registration and commercialization of products through in-licensing and flexible partnerships. U0126 manufacturer Some experts said that in the research and development of chemical medicine, the possibility of large medicines is getting smaller and smaller, and with the popularization of precision treatment, small medicines (high-efficiency medicines) are being introduced more and more. U0126 supplier As one of the world’s largest API producers and exporters, China’s chemical API production and operating income show steady growth. U0126 vendor Our pharma and biotech offering includes registration and commercialization of products through in-licensing and flexible partnerships. U0126 factory Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma.
